Insights

Gathering insights about TenX…

Similar companies to TenX

TenX Tech Stack

TenX uses 8 technology products and services including Microsoft Clarity, WordPress, jQuery Migrate, and more. Explore TenX's tech stack below.

Microsoft Clarity
Analytics
WordPress
Content Management System
jQuery Migrate
Javascript Libraries
Elementor
Page Builders
PHP
Programming Languages
X-XSS-Protection
Security
TablePress
Web Platform Extensions
Apache
Web Servers

Media & News

Tenax Therapeutics Reports First Quarter 2025 Financial Results and Provides Corporate Update
Phase 3 LEVEL Enrollment Completion for TNX-103 in PH-HFpEF Targeted Around Year-End 2025, with Topline Data Expected Middle of 2026
May 14, 2025 | www.globenewswire.com
Tenax: Phase 3 Heart Failure Program Continues With 2 Key Catalysts
Tenax Therapeutics is advancing levosimendan in two phase 3 studies for PH-HFpEF, with LEVEL-2 starting in 2025 and topline data from LEVEL expected mid-2026. Levosimendan could be the first disease-modifying therapy for PH-HFpEF, with prior phase 2 success in improving exercise capacity. The company raised $25 million in March 2025, ensuring sufficient funding through 2027 to meet clinical milestones.
Apr 16, 2025 | seekingalpha.com
Tenax Therapeutics to Participate in the 24th Annual Needham Virtual Healthcare Conference
CHAPEL HILL, N.C., March 31, 2025 (GLOBE NEWSWIRE) -- Tenax Therapeutics, Inc. (Nasdaq: TENX) (“Tenax Therapeutics” or the “Company”), a Phase 3, development-stage pharmaceutical company using clinical insights to develop novel cardiopulmonary therapies, today announced that the Company will present at the 24th Annual Needham Virtual Healthcare Conference, which is taking place virtually from April 7-10, 2025.
Mar 31, 2025 | www.globenewswire.com
Tenax Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update
Successfully Completed Private Placements with Aggregate Gross Proceeds of Approximately $125 Million to Support Advancement of Two Registrational Studies for TNX-103 in PH-HFpEF and Fund Operations through 2027
Mar 25, 2025 | www.globenewswire.com
Tenax Therapeutics Announces $25 Million Private Placement
CHAPEL HILL, N.C., March 05, 2025 (GLOBE NEWSWIRE) -- Tenax Therapeutics, Inc. (Nasdaq: TENX) (the “Company” or “Tenax Therapeutics”), a Phase 3, development-stage pharmaceutical company using clinical insights to develop novel cardiopulmonary therapies, today announced that it has entered into a securities purchase agreement for a private placement financing with RTW Investments, which is expected to result in total gross proceeds of approximately $25 million to the Company, before deducting placement agent fees and other private placement expenses.
Mar 05, 2025 | www.globenewswire.com
Tenax Therapeutics Expands Phase 3 LEVEL Program, Advancing Two TNX-103 (Oral Levosimendan) Registrational Studies for the Treatment of PH-HFpEF
Amendment to Enlarge Phase 3 LEVEL Study, Increasing Statistical Powering, Accepted by FDA, Expected to be Fully Enrolled Around Year End 2025
Mar 05, 2025 | www.globenewswire.com
Tenax Therapeutics to Participate in the Leerink Partners 2025 Global Healthcare Conference
CHAPEL HILL, N.C., March 03, 2025 (GLOBE NEWSWIRE) -- Tenax Therapeutics, Inc. (Nasdaq: TENX) (“Tenax Therapeutics” or the “Company”), a Phase 3, development-stage pharmaceutical company focused on identifying, developing and commercializing products that address cardiovascular and pulmonary diseases with high unmet medical need, today announced that the Company will participate in a fireside chat at the Leerink Partners 2025 Global Healthcare Conference, which is taking place from March 10-12, 2025, in Miami, FL.
Mar 03, 2025 | www.globenewswire.com

TenX's Email Address Formats

TenX uses at least 2 format(s):

TenX Email Formats	Example	Percentage
First.Last@analytics.com.pk	John.Doe@analytics.com.pk	96%
First.Middle@analytics.com.pk	John.Michael@analytics.com.pk	4%
First@tenx.ai	John@tenx.ai	63%
First.Last@tenx.ai	John.Doe@tenx.ai	37%

Frequently Asked Questions

Where is TenX's headquarters located?

TenX's main headquarters is located at 700 Canal St, Stamford, Connecticut 06902, US. The company has employees across 5 continents, including AsiaNorth AmericaEurope.

What is TenX's stock symbol?

TenX is a publicly traded company; the company's stock symbol is TENX.

What is TenX's official website and social media links?

TenX's official website is tenx.ai and has social profiles on LinkedIn.

How much revenue does TenX generate?

As of July 2025, TenX's annual revenue reached $15M.

What is TenX's NAICS code?

TenX's NAICS code is 5415 - Computer Systems Design and Related Services.

How many employees does TenX have currently?

As of July 2025, TenX has approximately 224 employees across 5 continents, including AsiaNorth AmericaEurope. Key team members include Chief Executive Officer: Q. Q.Chief Data Scientist: A. A.Vice President Of International Sales: W. A. Q.. Explore TenX's employee directory with LeadIQ.

What industry does TenX belong to?

TenX operates in the IT Services and IT Consulting industry.

What technology does TenX use?

TenX's tech stack includes Microsoft ClarityWordPressjQuery MigrateElementorPHPX-XSS-ProtectionTablePressApache.

What is TenX's email format?

TenX's email format typically follows the pattern of . Find more TenX email formats with LeadIQ.

When was TenX founded?

TenX was founded in 2015.

TenX

IT Services and IT ConsultingUnited States201-500 Employees

As a global tech agency, we operate as a service provider, product lab, and strategic investor, collaborating with businesses to fuel growth. Focused on business results, we've consistently delivered powerful solutions, achieving global success with clients ranging from ambitious startups to Fortune 500 companies.